Codexis to Present Data Highlighting Three Gene Therapy Programs at the ASGCT 25th Annual Meeting
May 02, 2022 16:35 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced two poster...
Codexis to Report First Quarter 2022 Financial Results on May 5
April 21, 2022 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will...
Codexis and seqWell Announce Strategic Investment and Partnership Initiation
April 21, 2022 08:00 ET
|
Codexis, Inc.
seqWell raises $7M Series C funding, led by CodexisCurrent investors Research Corporation Technologies and BroadOak Capital Partners also participated in the roundNew funding will be used to...
Codexis and Molecular Assemblies Announce Results of First Collaboration on a Proprietary High Performing DNA Polymerase to Supercharge Fully Enzymatic DNA Synthesis
April 12, 2022 08:00 ET
|
Codexis, Inc.
Molecular Assemblies has pioneered Fully Enzymatic Synthesis™ (or FES™) technology with an in-process purification step to overcome the length, purity, and accuracy limitations of the current chemical...
Codexis to Participate in the Cowen 42nd Annual Health Care Conference
March 01, 2022 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management...
Codexis Reports Fourth Quarter and Fiscal Year 2021 Financial Results
February 24, 2022 16:05 ET
|
Codexis, Inc.
Record Annual Total Revenue of $104.8M, Representing Eighth Consecutive Year of Revenue Growth Company Guides to 2022 Total Revenues of $152-$158M; Product Revenues of $112-$118M REDWOOD CITY,...
Codexis to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24
February 10, 2022 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will...
Codexis Announces FDA Orphan Drug and Rare Pediatric Disease Designations for CDX 6512 for the Treatment of Homocystinuria
January 24, 2022 08:00 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that the U.S....
Codexis to Participate in the H.C. Wainwright Virtual BioConnect Conference
January 05, 2022 08:00 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management...
Codexis Launches Codex® HiTemp Reverse Transcriptase to Address Key Challenges in One-Step Assays for RNA Detection in PCR Testing, including COVID-19 Testing
December 15, 2021 08:00 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the launch of...